tiprankstipranks
Trending News
More News >
Statera BioPharma (STAB)
OTHER OTC:STAB
US Market

Statera BioPharma (STAB) Ratios

Compare
190 Followers

Statera BioPharma Ratios

STAB's free cash flow for Q3 2022 was $0.75. For the 2022 fiscal year, STAB's free cash flow was decreased by $ and operating cash flow was $-2.31. See a summary of the company’s cash flow.
Ratios
TTM
Dec 21Dec 20Dec 19Dec 18
Liquidity Ratios
Current Ratio
0.37 0.20 <0.01--
Quick Ratio
0.37 0.20 0.10--
Cash Ratio
0.16 0.13 <0.01--
Solvency Ratio
-7.68 -2.82 -0.79--
Operating Cash Flow Ratio
-2.51 -1.10 -0.06--
Short-Term Operating Cash Flow Coverage
-6.16 -2.67 -0.13--
Net Current Asset Value
$ -18.52M$ -3.77M$ -4.21M--
Leverage Ratios
Debt-to-Assets Ratio
0.77 1.93 1.09K--
Debt-to-Equity Ratio
-10.37 -0.55 -0.43--
Debt-to-Capital Ratio
1.11 -1.21 -0.75--
Long-Term Debt-to-Capital Ratio
1.17 0.00 0.00--
Financial Leverage Ratio
-13.50 -0.28 >-0.01--
Debt Service Coverage Ratio
-7.34 -1.23 -1.29--
Interest Coverage Ratio
0.00 -9.29 -22.65--
Debt to Market Cap
2.13K 0.01 0.01--
Interest Debt Per Share
0.46 0.12 0.08--
Net Debt to EBITDA
0.37 -0.54 -0.76--
Profitability Margins
Gross Profit Margin
0.00%0.00%0.00%--
EBIT Margin
0.00%0.00%0.00%--
EBITDA Margin
0.00%0.00%0.00%--
Operating Profit Margin
0.00%0.00%0.00%--
Pretax Profit Margin
0.00%0.00%0.00%--
Net Profit Margin
0.00%0.00%0.00%--
Continuous Operations Profit Margin
0.00%0.00%0.00%--
Net Income Per EBT
171.20%109.35%103.85%--
EBT Per EBIT
103.59%115.16%114.56%--
Return on Assets (ROA)
-823.86%-1277.14%-202924.55%--
Return on Equity (ROE)
6677.48%361.75%79.53%--
Return on Capital Employed (ROCE)
-990.93%292.90%66.85%--
Return on Invested Capital (ROIC)
-1141.10%694.97%123.26%--
Return on Tangible Assets
-1689.72%-1277.14%-202924.55%--
Earnings Yield
-4967430.79%-10.29%-2.61%--
Efficiency Ratios
Receivables Turnover
0.00 0.00 0.00--
Payables Turnover
0.12 0.00 0.00--
Inventory Turnover
0.00 0.00 0.00--
Fixed Asset Turnover
0.00 0.00 0.00--
Asset Turnover
0.00 0.00 0.00--
Working Capital Turnover Ratio
0.00 0.00 0.00--
Cash Conversion Cycle
-2.96K 0.00 0.00--
Days of Sales Outstanding
0.00 0.00 0.00--
Days of Inventory Outstanding
0.00 0.00 0.00--
Days of Payables Outstanding
2.96K 0.00 0.00--
Operating Cycle
0.00 0.00 0.00--
Cash Flow Ratios
Operating Cash Flow Per Share
-0.80 -0.20 >-0.01--
Free Cash Flow Per Share
-0.81 -0.20 >-0.01--
CapEx Per Share
<0.01 <0.01 0.00--
Free Cash Flow to Operating Cash Flow
1.01 1.00 1.00--
Dividend Paid and CapEx Coverage Ratio
-154.09 -527.36 0.00--
Capital Expenditure Coverage Ratio
-154.09 -527.36 0.00--
Operating Cash Flow Coverage Ratio
-1.73 -2.54 -0.13--
Operating Cash Flow to Sales Ratio
0.00 0.00 0.00--
Free Cash Flow Yield
-397315.22%-3.96%-0.19%--
Valuation Ratios
Price-to-Earnings (P/E) Ratio
>-0.01 -9.72 -38.38--
Price-to-Sales (P/S) Ratio
0.00 0.00 0.00--
Price-to-Book (P/B) Ratio
>-0.01 -35.15 -30.53--
Price-to-Free Cash Flow (P/FCF) Ratio
>-0.01 -25.24 -534.62--
Price-to-Operating Cash Flow Ratio
>-0.01 -25.29 -534.62--
Price-to-Earnings Growth (PEG) Ratio
>-0.01 -0.03 0.65--
Price-to-Fair Value
>-0.01 -35.15 -30.53--
Enterprise Value Multiple
0.37 -50.23 -55.20--
Enterprise Value
14.42M 129.92M 130.31M--
EV to EBITDA
0.37 -50.23 -55.20--
EV to Sales
0.00 0.00 0.00--
EV to Free Cash Flow
-0.51 -25.51 -542.12--
EV to Operating Cash Flow
-0.51 -25.56 -542.12--
Tangible Book Value Per Share
-0.35 -0.14 -0.16--
Shareholders’ Equity Per Share
-0.04 -0.14 -0.16--
Tax and Other Ratios
Effective Tax Rate
-0.71 -0.09 -0.04--
Revenue Per Share
0.00 0.00 0.00--
Net Income Per Share
-4.97 -0.52 -0.13--
Tax Burden
1.71 1.09 1.04--
Interest Burden
0.60 1.10 1.04--
Research & Development to Revenue
0.00 0.00 0.00--
SG&A to Revenue
0.00 0.00 0.00--
Stock-Based Compensation to Revenue
0.00 0.00 0.00--
Income Quality
0.28 0.42 0.07--
Currency in USD